Cytogen Inc Cash Flow Conversion Efficiency

Latest as of December 2025: -0.059x

Cytogen Inc cash flow conversion efficiency. Based on the latest financial reports, Cytogen Inc (217330) has a cash flow conversion efficiency ratio of -0.059x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-2.13 Billion ≈ $-1.44 Million USD) by net assets (₩35.99 Billion ≈ $24.39 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Cytogen Inc (2014–2025)

Cash flow conversion efficiency of Cytogen Inc from 2014 to 2025. This chart illustrates how Cytogen Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 217330 stock price for real-time trading data and today's change.

Cytogen Inc Cash Flow Conversion Ratio Explained

Cytogen Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Cytogen Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Cytogen Inc ranked by their cash flow conversion efficiency. Also see Cytogen Inc (217330) market capitalisation for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Space Com TA:SCC	-0.893x
Namuga Co. Ltd KQ:190510	0.079x
Culp, Inc. Common Stock NYSE:CULP	-0.022x
Ferroamp Elektronik AB ST:FERRO	-0.003x
Reading International Inc NASDAQ:RDI	-0.136x
HeiTech Padu Bhd KLSE:5028	-0.223x
Star Equity Holdings Inc NASDAQ:STRR	-0.059x
Dong A Eltek Co. Ltd KQ:088130	0.145x

Annual Cash Flow Conversion Efficiency for Cytogen Inc (2014–2025)

The table below shows the annual cash flow conversion efficiency of Cytogen Inc from 2014 to 2025. Review 217330 financial flexibility score to assess the company's free cash flow relative to its total liabilities.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	₩35.99 Billion ≈ $24.39 Million	₩-6.95 Billion ≈ $-4.71 Million	-0.193x	+1.50%
2024-12-31	₩48.58 Billion ≈ $32.92 Million	₩-9.53 Billion ≈ $-6.46 Million	-0.196x	-37.81%
2023-12-31	₩53.36 Billion ≈ $36.16 Million	₩-7.59 Billion ≈ $-5.15 Million	-0.142x	+87.38%
2022-12-31	₩5.66 Billion ≈ $3.83 Million	₩-6.38 Billion ≈ $-4.32 Million	-1.128x	-396.17%
2021-12-31	₩23.01 Billion ≈ $15.59 Million	₩-5.23 Billion ≈ $-3.54 Million	-0.227x	+6.68%
2020-12-31	₩18.34 Billion ≈ $12.43 Million	₩-4.47 Billion ≈ $-3.03 Million	-0.244x	-29.58%
2019-12-31	₩17.92 Billion ≈ $12.14 Million	₩-3.37 Billion ≈ $-2.28 Million	-0.188x	-49.56%
2018-12-31	₩22.04 Billion ≈ $14.94 Million	₩-2.77 Billion ≈ $-1.88 Million	-0.126x	+72.70%
2017-12-31	₩4.73 Billion ≈ $3.21 Million	₩-2.18 Billion ≈ $-1.48 Million	-0.460x	+90.73%
2016-12-31	₩475.51 Million ≈ $322.25K	₩-2.36 Billion ≈ $-1.60 Million	-4.969x	-551.88%
2015-12-31	₩2.66 Billion ≈ $1.80 Million	₩-2.03 Billion ≈ $-1.37 Million	-0.762x	+64.00%
2014-12-31	₩484.59 Million ≈ $328.40K	₩-1.03 Billion ≈ $-695.41K	-2.118x	--

About Cytogen Inc

KQ:217330 Korea Diagnostics & Research

Market Cap

$34.79 Million

₩51.33 Billion KRW

Market Cap Rank

#23040 Global

#1554 in Korea

Share Price

₩2225.00

Change (1 day)

-4.09%

52-Week Range

₩2225.00 - ₩9420.00

All Time High

₩22599.98